2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 385

Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study
Abstract Number: 2098

Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas
Abstract Number: 786

Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis
Abstract Number: 2536

Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Abstract Number: 820

Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis
Abstract Number: 1985

Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis
Abstract Number: 493

Diversity Analysis of Intestinal Flora in Patients with Rheumatoid Arthritis
Abstract Number: 1465

Diversity Analysis of Intestinal Flora in Patients with Sjogren’s Syndrome
Abstract Number: 2469

Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance
Abstract Number: 2906

DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Abstract Number: 2395

DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Abstract Number: 1030

DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients
Abstract Number: 2396

DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
Abstract Number: 789

DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].